| Literature DB >> 35535461 |
Jiratchaya Puangseree1, Rangsiya Prathan1,2, Songsak Srisanga1,2, Sunpetch Angkittitrakul3, Rungtip Chuanchuen1,2.
Abstract
This study aimed to determine the epidemiology and association of antimicrobial resistance (AMR) among Escherichia coli and Salmonella in Thailand. The E. coli (n = 1047) and Salmonella (n = 816) isolates from pigs, pork and humans were screened for 18 replicons including HI1, HI2, I1-γ, X, L/M, N, FIA, FIB, W, Y, P, FIC, A/C, T, FIIAs, F, K and B/O using polymerase chain reaction-based replicon typing. The E. coli (n = 26) and Salmonella (n = 3) isolates carrying IncF family replicons, ESBL and/or mcr genes were determined for FAB formula. IncF represented the major type of plasmids. Sixteen and eleven Inc groups were identified in E. coli (85.3%) and Salmonella (25.7%), respectively. The predominant replicon patterns between E. coli and Salmonella were IncK-F (23.7%) and IncF (46.2%). Significant correlations (P < 0.05) were observed between plasmid-replicon type and resistance phenotype. Plasmid replicon types were significantly different among sources of isolates and sampling periods. The most common FAB types between E. coli and Salmonella were F2:A-:B- (30.8%) and S1:A-:B- (66.7%), respectively. In conclusion, various plasmids present in E. coli and Salmonella. Responsible and prudent use of antimicrobials is suggested to reduce the selective pressures that favour the spread of AMR determinants. Further studies to understand the evolution of R plasmids and their contribution to the dissemination of AMR genes are warranted.Entities:
Keywords: Escherichia coli; Salmonella; Thailand; incompatibility group; plasmid
Mesh:
Substances:
Year: 2022 PMID: 35535461 PMCID: PMC9214845 DOI: 10.1017/S0950268822000814
Source DB: PubMed Journal: Epidemiol Infect ISSN: 0950-2688 Impact factor: 4.434
Sources and number of E. coli (n = 1047) and Salmonella (n = 816) used in this study
| Year | No. of | Total | No. of | Total | ||||
|---|---|---|---|---|---|---|---|---|
| Pig | Pork | Human | Pig | Pork | Human | |||
| 2005–2010 | 309 | – | – | 309 | 8 | 104 | 52 | 164 |
| 2010–1014 | 123 | 223 | 103 | 449 | 67 | 263 | 85 | 415 |
| 2015–2019 | 265 | 24 | – | 289 | 94 | 143 | – | 237 |
| Total | 697 | 247 | 103 | 1047 | 169 | 510 | 137 | 816 |
| Grand total | 1047 | 816 | ||||||
AMR and ESBL production in E. coli (n = 1047) and Salmonella (n = 816) isolates that included in this study
| Antimicrobial drugs/enzymes | No. of | No. of | ||||||
|---|---|---|---|---|---|---|---|---|
| Pig ( | Pork ( | Human ( | Total ( | Pig ( | Pork ( | Human ( | Total ( | |
| AMP | 623 (89.4) | 200 (81.0) | 62 (60.2) | 885 (84.5) | 148 (87.6) | 395 (77.5) | 89 (65.0) | 632 (77.5) |
| CHP | 423 (60.7) | 83 (33.6) | 17 (16.5) | 523 (50.0) | 25 (14.8) | 147 (28.8) | 83 (60.6) | 255 (31.3) |
| CIP | 220 (31.6) | 8 (3.2) | 7 (6.8) | 235 (22.4) | 0 (0) | 2 (0.4) | 21 (15.3) | 23 (2.8) |
| GEN | 279 (40.0) | 29 (11.7) | 14 (13.6) | 322 (30.8) | 30 (17.8) | 69 (13.5) | 79 (57.7) | 178 (21.8) |
| STR | 453 (65.0) | 114 (46.2) | 11 (10.7) | 578 (55.2) | 109 (64.5) | 323 (63.3) | 123 (89.8) | 555 (68.0) |
| SMZ | 521 (74.7) | 121 (49.0) | 38 (36.9) | 680 (64.9) | 130 (76.9) | 408 (80) | 103 (75.2) | 641 (78.6) |
| TET | 617 (88.5) | 169 (68.4) | 51 (49.5) | 837 (79.9) | 140 (82.8) | 426 (83.5) | 106 (77.4) | 672 (82.4) |
| TMP | 475 (68.1) | 127 (51.4) | 34 (33.0) | 636 (60.7) | 95 (56.2) | 241 (47.3) | 64 (46.7) | 400 (49.0) |
| COL | 160 (23.0) | 15 (6.1) | 0 (0) | 175 (16.7) | 2 (1.2) | 7 (1.4) | 0 (0) | 9 (1.1) |
| ESBLs | 140 (20.1) | 7 (2.8) | 8 (7.8) | 155 (14.8) | 2 (1.2) | 19 (3.7) | 0 (0) | 21 (2.6) |
AMP, ampicillin; CHP, chloramphenicol; CIP, ciprofloxacin; GEN, gentamycin; STR, streptomycin; SMZ, sulphamethoxazole; TET, tetracycline; TMP, trimethoprim; COL, colistin.
Percentage of Inc group of plasmids of E. coli (n = 1047) and Salmonella (n = 816) isolated from pig, pork and human
| Target bacteria | Category | Sub-category | No. of isolates for each replicon (%) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HI1 | HI2 | I1- | X | N | FIA | FIB | W | Y | P | FIC | A/C | FIIAs | K | B/O | F | |||
| Overall ( | 137 (13.1) | 19 (1.8) | 129 (12.3) | 1 (0.1) | 112 (10.7) | 59 (5.6) | 290 (27.7) | 1 (0.1) | 135 (12.9) | 23 (2.2) | 39 (3.7) | 12 (1.1) | 146 (13.9) | 634 (60.6) | 16 (1.5) | 512 (48.9) | ||
| By source ( | Pig ( | 120 (17.2)a | 19 (2.7)a | 108 (15.5)a | 1 (0.1)a | 93 (13.3)a | 49 (7)a | 240 (34.4)a | 1 (0.1)a | 105 (15.1)a | 9 (1.3)a | 19 (2.7)a | 5 (0.7)a | 127 (18.2)a | 509 (73)a | 15 (2.2)a | 405 (58.1)a | |
| Pork ( | 11 (4.5)b | 0b | 14 (5.7)b | 0a | 16 (6.5)b | 5 (2)b | 32 (13)b | 0a | 24 (9.7)b | 7 (2.8)a,b | 18 (7.3)b | 6 (2.4)b | 18 (7.3)b | 106 (42.9)b | 0b | 73 (29.6)b | ||
| Human ( | 6 (5.8)b | 0a,b | 7 (6.8)b | 0a | 3 (2.9)b | 5 (4.9)a,b | 18 (17.5)b | 0a | 6 (5.8)b | 7 (6.8)b | 2 (1.9)a,b | 1 (1)a,b | 1 (1)c | 19 (18.4)c | 1 (1)a,b | 34 (33)b | ||
| By year | 2007–2010 ( | 63 (20.4)a | 19 (6.1)a | 86 (27.8)a | 0a | 46 (14.9)a | 28 (9.1)a | 111 (35.9)a | 0a | 31 (10.0)a | 0a | 5 (1.6)a | 0a | 33 (10.7)a | 246 (79.6)a | 11 (3.6)a | 202 (65.4)a | |
| 2011–2014 ( | 33 (7.3)b | 0b | 29 (6.5)b | 0a | 32 (7.1)b | 16 (3.6)b | 70 (15.6)b | 0a | 46 (10.2)a | 18 (4.0)b | 27 (6.0)b | 10 (2.2)b | 24 (5.3)b | 163 (36.3)b | 1 (0.2)b | 140 (31.2)b | ||
| 2015–2019 ( | 41 (14.2)a | 0b | 14 (4.8)b | 1 (0.3)a | 34 (11.8)a | 15 (5.2)ab | 109 (37.7)a | 1 (0.3)a | 58 (20.1)b | 5 (1.7)b | 7 (2.4)a | 2 (0.7)ab | 89 (30.8)c | 225 (77.9)a | 4 (1.4)ab | 170 (58.8)a | ||
| Overall ( | 21 (2.6) | 2 (0.2) | 35 (4.3) | na | 20 (2.5) | na | 19 (2.3) | na | 40 (4.9) | na | 6 (0.7) | 15 (1.8) | 81 (9.9) | na | 1 (0.1) | 22 (2.7) | ||
| By source ( | Pig ( | 3 (1.8)a,b | 0a | 18 (10.7)a | na | 1 (0.6)a | na | 6 (3.6)a | na | 34 (20.1)a | na | 0a | 0a | 12 (7.1)a | na | 0a | 8 (4.7)a | |
| Pork ( | 18 (3.5)a | 2 (0.4)a | 14 (2.7)b | na | 6 (1.2)a | na | 13 (2.5)a,b | na | 4 (0.8)b | na | 6 (1.2)a | 9 (1.8)a,b | 36 (7.1)a | na | 0a | 14 (2.7)a | ||
| Human ( | 0b | 0a | 3 (2.2)b | na | 13 (9.5)b | na | 0b | na | 2 (1.5)b | na | 0a | 6 (4.4)b | 33 (24.1)b | na | 1 (0.7)a | 0b | ||
| By year | 2005–2010 ( | 0a | 2 (1.2)a | 7 (4.3)ab | na | 15 (9.1)a | na | 8 (4.9)a | na | 1 (0.6)a | na | 5 (3.0)a | 3 (1.8)a | 10 (6.1)a | na | 0a | 9 (5.5)a | |
| 2011–2014 ( | 15 (3.6)b | 0a | 11 (2.7)a | na | 5 (1.2)b | na | 10 (2.4)ab | na | 6 (1.4)a | na | 1 (0.2)b | 7 (1.7)a | 50 (12.0)b | na | 1 (0.2)a | 11 (2.7)ab | ||
| 2015–2019 ( | 6 (2.5)ab | 0a | 17 (7.2)b | na | 0b | na | 1 (0.4)b | na | 33 (13.9)b | na | 0b | 5 (2.1)a | 21 (8.9)ab | na | 0a | 2 (0.8)b | ||
a,b,cValues with different superscripts in the same column and category indicated statistical difference (P < 0.05) among E. coli or Salmonella from different sources or years.
na, no associations due to the lack of the corresponding replicon types.
Fig. 1.Prevalence of replicon types of (A) E. coli and (B) Salmonella sorted by year, 2007–2010 (n = 309, 164), 2011–2014 (n = 449, 415) and 2015–2019 (n = 289, 237), respectively.
Replicon patterns among E. coli (n = 1047) and Salmonella (n = 816)
| Replicon pattern | ||||||
|---|---|---|---|---|---|---|
| No. of isolates (%) | No. of ESBL-producing isolates (%) | No. of | No. of isolates (%) | No. of ESBL-producing isolates (%) | No. of | |
| A/C | 1 (0.1) | – | – | 10 (4.8) | 5 (23.8) | – |
| A/C-F | 3 (0.3) | 1 (0.6) | – | 1 (0.5) | – | – |
| A/C-K | 1 (0.1) | – | – | – | – | – |
| A/C-K-F | 2 (0.2) | – | – | – | – | – |
| B/O | 1 (0.1) | – | – | 1 (0.5) | – | – |
| B/O-K-F | 10 (1.1) | – | 1 (0.9) | – | – | – |
| F | 129 (14.4) | 13 (8.4) | 8 (7.3) | 97 (46.2) | 1 (5.3) | 3 (60.0) |
| F-Y-K | 36 (4.0) | 11 (7.1) | 4 (3.7) | – | – | – |
| HI1 | 8 (0.9) | 2 (1.3) | 2 (1.8) | 10 (4.8) | 8 (42.1) | 1 (20.0) |
| HI1-F | 10 (1.1) | 1 (0.6) | 5 (4.6) | 7 (3.0) | 1 (5.3) | 1 (20.0) |
| HI1-HI2-F | 4 (0.4) | – | 4 (3.7) | – | – | – |
| HI1-HI2-K-F | 15 (1.7) | 7 (4.5) | 11 (10.1) | – | – | – |
| HI1-I1- | – | – | – | 4 (1.9) | 4 (21.1) | – |
| HI1-I1- | 2 (0.2) | – | – | – | – | – |
| HI1-I1- | 5 (0.6) | – | 5 (4.6) | – | – | – |
| HI1-I1- | 3 (0.3) | 1 (0.6) | 1 (0.9) | – | – | – |
| HI1-K | 11 (1.2) | 1 (0.6) | 7 (6.4) | – | – | – |
| HI1-K-F | 24 (2.7) | 2 (1.3) | 6 (5.5) | – | – | – |
| HI1-N | 5 (0.6) | – | – | – | – | – |
| HI1-N-A/C-K | 1 (0.1) | – | – | – | – | – |
| HI1-N-F | 8 (0.9) | 3 (1.9) | 3 (2.8) | – | – | – |
| HI1-N-K | 13 (1.5) | 8 (5.2) | – | – | – | – |
| HI1-N-K-F | 11 (1.2) | 2 (1.3) | – | – | – | – |
| HI1-N-Y | 1 (0.1) | – | – | – | – | – |
| HI1-N-Y-F | 1 (0.1) | – | – | – | – | – |
| HI1–N-Y-K | 1 (0.1) | – | – | – | – | – |
| HI1-N-Y-K-F | 2 (0.2) | – | – | – | – | – |
| HI1-Y | 1 (0.1) | 1 (0.6) | – | – | – | – |
| HI1-Y-A/C-K | 1 (0.1) | 1 (0.6) | – | – | – | – |
| HI1-Y-F | 1 (0.1) | 1 (0.6) | – | – | – | – |
| HI1-Y-K | 8 (0.9) | 8 (5.2) | 1 (0.9) | – | – | – |
| HI1-Y-K-F | 1 (0.1) | – | – | – | – | – |
| HI2 | – | – | – | 1 (0.5) | – | – |
| HI2-N | – | – | – | 1 (0.5) | – | – |
| I1- | 8 (0.9) | 1 (0.6) | – | 16 (7.6) | – | – |
| I1-A/C-F | 1 (0.1) | – | 1 (0.9) | – | – | – |
| I1-F | 16 (1.8) | 4 (2.6) | 1 (0.9) | 3 (1.4) | – | – |
| I1- | 1 (0.1) | – | – | – | – | – |
| I1- | 9 (1.0) | – | – | – | – | – |
| I1- | 61 (6.8) | 42 (27.3) | 4 (3.7) | – | – | – |
| I1- | 1 (0.1) | – | – | – | – | – |
| I1- | 1 (0.1) | – | – | – | – | – |
| I1- | 6 (0.7) | 3 (1.9) | – | 12 (5.7) | – | – |
| I1- | 1 (0.1) | – | – | – | – | – |
| I1- | 3 (0.3) | – | – | – | – | – |
| I1- | 3 (0.3) | 2 (1.3) | 1 (0.9) | – | – | – |
| I1- | 8 (0.9) | 4 (2.6) | 2 (1.8) | – | – | – |
| K | 106 (11.9) | 1 (0.6) | 3 (2.8) | – | – | – |
| K-F | 212 (23.7) | 17 (11.0) | 20 (18.3) | – | – | – |
| N | 4 (0.4) | – | 1 (0.9) | 15 (7.1) | – | – |
| N-A/C | – | – | – | 4 (1.9) | – | – |
| N-F | 9 (1.0) | 5 (3.2) | 2 (1.8) | – | – | – |
| N-K | 25 (2.8) | 1 (0.6) | 3 (2.8) | – | – | – |
| N-K-F | 22 (2.5) | 4 (2.6) | 5 (4.6) | – | – | – |
| N-Y | 1 (0.1) | – | – | – | – | – |
| N-Y-A/C-K | 1 (0.1) | – | – | – | – | – |
| N-Y-K | 1 (0.1) | – | – | – | – | – |
| N-Y-K-F | 5 (0.6) | 3 (1.9) | – | – | – | – |
| P | 5 (0.6) | – | – | – | – | – |
| P-F | 3 (0.3) | – | – | – | – | – |
| P-K | 3 (0.3) | – | – | – | – | – |
| P-K-F | 3 (0.3) | – | – | – | – | – |
| W-K-F | 1 (0.1) | – | – | – | – | – |
| X-F | 1 (0.1) | – | – | – | – | – |
| Y | 12 (1.3) | – | 3 (2.8) | 28 (13.3) | – | – |
| Y-F | 12 (1.3) | 2 (1.3) | 5 (4.6) | – | – | – |
| Y-K | 21 (2.4) | 2 (1.3) | – | – | – | – |
| Y-P-F | 1 (0.1) | – | – | – | – | – |
| Y-P-K | 2 (0.2) | – | – | – | – | – |
| Y-P-K-F | 4 (0.4) | – | – | – | – | – |
| Positive at least one replicon type | 893 (85.3) | 154 (99.4) | 109 (100) | 210 (25.7) | 19 (90.5) | 5 (41.7) |
| No replicon pattern | 154 (14.7) | 1 (0.6) | – | 606 (74.3) | 2 (9.5) | 7 (58.3) |
| Total | 1047 | 155 | 109 | 816 | 21 | 12 |
F, at least one replicon type of IncF family replicon (i.e. FIA, FIB, FIC, FIIAs and F) was found.
OR between the presence of replicon types and AMR or ESBL-producing E. coli (n = 1047) and Salmonella (n = 816)
| Bacterial strain | Type of replicons | OR of AMR phenotype (95% CI) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| AMP | CHP | CIP | GEN | STR | SMZ | TET | TMP | COL | ESBL producer | ||
| HI1 | 4.96 (2.0–12.4)a | 2.62 (1.8–3.9)a | 5.46 (3.7–8.0)a | 5.0 (3.4–7.3)a | 3.7 (2.4–5.7)a | 4.2 (2.4–7.4)a | 12.1 (3.8–38.4)a | 2.56 (1.7–3.9)a | 6.83 (4.6–10.1)a | 2.5 (1.6–3.8)a | |
| HI2 | na | na | na | – | na | na | na | – | 20.34 (6.7–62.1)a | 3.36 (1.3–8.7)a | |
| I1- | – | – | 0.52 (0.3–0.9)b | 4.77 (3.2–7.0)a | 2.5 (1.7–3.9)a | – | – | 0.55 (0.4–0.8)b | – | 6.33 (4.2–9.5)a | |
| N | 4.95 (1.8–13.7)a | 2.78 (1.8–4.3)a | 3.41 (2.3–5.1)a | 2.34 (1.6–3.5)a | 1.83 (1.2–2.8)a | 2.8 (1.6–4.7)a | 3.3 (1.6–6.9)a | 2.95 (1.8–4.8)a | 1.79 (1.1–2.8)a | 1.82 (1.1–2.9)a | |
| FIA | – | – | 3.67 (2.2–6.3)a | – | 2.0 (1.1–3.6)a | 5.22 (2.1–13.2)a | 2.61 (1.02–6.6)a | 2.53 (1.3–4.8)a | – | 0.19 (0.04–0.8)b | |
| FIB | 3.16 (1.9–5.3)a | 1.62 (1.2–2.1)a | 2.0 (1.5–2.7)a | – | 1.56 (1.2–2.1)a | 2.15 (1.6–3.0)a | 2.82 (1.8–4.3)a | 1.58 (1.2–2.1)a | 2.36 (1.7–3.3)a | – | |
| Y | 3.37 (1.5–7.4)a | – | 1.61 (1.1–2.4)a | 1.92 (1.3–2.8)a | 2.39 (1.6–3.6)a | – | 2.17 (1.2–3.9)a | 1.91 (1.3–2.9)a | 1.93 (1.3–3.0)a | 2.57 (1.7–4.0)a | |
| P | – | – | na | 0.1 (0.01–0.7)b | – | – | – | – | na | na | |
| FIC | – | 0.28 (0.1–0.6)b | – | – | – | – | – | – | – | – | |
| A/C | na | – | – | – | – | – | – | – | – | – | |
| FIIAs | – | – | – | 0.65 (0.4–0.9)b | – | – | – | – | 1.56 (1.02–2.3)a | 0.51 (0.2–0.9)b | |
| K | 2.38 (1.7–3.4)a | 2.39 (1.9–3.1)a | 1.77 (1.3–2.4)a | 1.99 (1.5–2.6)a | 2.2 (1.7–2.8)a | 2.38 (1.8–3.1)a | 3.3 (2.4–4.6)a | 2.07 (1.6–2.7)a | 1.47 (1.04–2.1)a | 2.0 (1.4–2.9)a | |
| B/O | – | – | – | – | – | – | na | 9.47 (1.3–72.0)a | 3.06 (1.1–8.5)a | na | |
| F | 2.17 (1.5–3.1)a | 1.87 (1.5–2.4)a | 1.4 (1.1–1.9)a | 2.55 (1.9–3.3)a | 1.57 (1.2–2.0)a | 1.59 (1.2–2.1)a | 3.0 (2.1–4.2)a | – | 2.76 (1.9–3.9)a | 3.23 (2.2–4.7)a | |
| HI1 | na | 46.8 (6.2–350.8)a | na | 4.04 (1.7–9.7)a | 0.22 (0.1–0.6)b | na | – | – | 11.9 (2.3–60.8)a | 159.9 (52.0–491.3)a | |
| HI2 | – | – | na | – | – | na | – | – | na | na | |
| I1- | – | – | na | 4.5 (2.3–9.0)a | – | – | – | – | na | 5.8 (1.8–18.3)a | |
| N | – | 44.3 (5.9–332.7)a | 14.4 (4.7–43.9)a | 8.8 (3.3–23.2)a | – | – | – | – | na | na | |
| FIB | – | 4.8 (1.8–13.0)a | na | – | na | – | na | – | – | na | |
| Y | 0.17 (0.1–0.5)b | na | – | – | na | na | na | – | na | na | |
| FIC | 0.1 (0.02–0.7)b | – | na | na | – | – | 0.2 (0.04–0.98)b | – | 20.1 (2.1–191.6)a | na | |
| A/C | na | 14.8 (3.3–65.9)a | na | 14.96 (4.2–53.7)a | na | na | na | – | na | 24.5 (7.5–80.0)a | |
| FIIAs | 0.15 (0.1–0.2)b | – | – | – | 0.36 (0.2–0.6)b | – | 0.2 (0.1–0.3)b | – | – | – | |
| F | – | 4.85 (2.0–12.0)a | na | – | na | – | na | – | – | – | |
OR > 1, the resistance to the drug increased with the presence of corresponding replicon types.
OR < 1, the resistance to the drug decreased with the presence of corresponding replicon types.
a,bStatistically significant association (95% CI did not cross 1) between the presence of plasmids in particular Inc groups and resistant or ESBL-producing strains.
–, no statistically significant association (95% CI cross 1) between the presence of plasmids in particular Inc groups and resistant or ESBL-producing strains.
na, no OR due to the lack of the corresponding replicon types.
AMP, ampicillin; CHP, chloramphenicol; CIP, ciprofloxacin; GEN, gentamycin; STR, streptomycin; SMZ, sulphamethoxazole; TET, tetracycline; TMP, trimethoprim; COL, colistin.
OR between each two replicon types presented in E. coli (n = 1047) and Salmonella (n = 816)
| Bacterial strain | Replicon type | OR of replicon types (95% CI) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HI1 | HI2 | I1- | N | FIA | FIB | Y | P | FIC | A/C | FIIAs | K | B/O | F | ||
| HI1 | nd | na | – | 5.58 (3.60–8.3)a | 0.11 (0.02–0.79)b | 1.55 (1.06–2.26)a | – | na | – | – | – | 1.62 (1.10–2.39)a | 3.10 (1.06–9.05)a | – | |
| HI2 | na | nd | na | na | na | na | na | na | na | na | na | – | na | na | |
| I1- | – | na | nd | 0.06 (0.01–0.41)b | – | – | – | – | – | – | 0.22 (0.09–0.55)b | 1.65 (1.11–2.47)a | 3.31 (1.14–9.73)a | 3.08 (2.05–4.62)a | |
| N | 5.58 (3.60–8.3)a | na | 0.06 (0.01–0.41)b | nd | – | 0.54 (0.32–0.89)b | – | na | – | – | – | 2.00 (1.28–3.11)a | na | – | |
| FIA | 0.11 (0.02–0.79)b | na | – | – | nd | 8.85 (4.84–16.18)a | – | – | – | – | – | – | – | 3.96 (2.12–7.43)a | |
| FIB | 1.55 (1.06–2.26)a | na | – | 0.54 (0.32–0.89)b | 8.85 (4.84–16.18)a | nd | – | – | 2.32 (1.22–4.42)a | – | – | 1.34 (1.01–1.78)a | 41.24 (5.42–313.65)a | 24.26 (15.43–38.14)a | |
| Y | – | na | – | – | – | – | nd | 3.77 (1.57–9.06)a | – | – | 1.67 (1.05–2.65)a | 1.64 (1.11–2.43)a | na | 0.66 (0.46–0.96)b | |
| P | na | na | – | na | – | – | 3.77 (1.57–9.06)a | nd | – | na | – | – | na | – | |
| FIC | – | na | – | – | – | 2.32 (1.22–4.42)a | – | – | nd | na | – | – | na | 2.15 (1.09–4.23)a | |
| A/C | – | na | – | – | – | – | – | na | na | nd | na | – | na | – | |
| FIIAs | – | na | 0.22 (0.09–0.55)b | – | – | – | 1.67 (1.05–2.65)a | – | – | na | nd | 3.86 (2.45–6.10)a | na | – | |
| K | 1.62 (1.10–2.39)a | – | 1.65 (1.11–2.47)a | 2.00 (1.28–3.11)a | 1.19 (0.69–2.06)a | 1.34 (1.01–1.78)a | 1.64 (1.11–2.43)a | – | – | – | 3.86 (2.45–6.10)a | nd | 9.98 (1.31–75.87)a | 1.59 (1.24–2.05)a | |
| B/O | 3.10 (1.06–9.05)a | na | 3.33 (1.14–9.73)a | na | – | 41.24 (5.42–313.65)a | na | na | na | na | na | 9.98 (1.31–75.87)a | nd | 16.12 (2.12–122.46)a | |
| F | – | na | 3.08 (2.05–4.62)a | – | 3.96 (2.12–7.43)a | 24.26 (15.43–38.14)a | 0.66 (0.46–0.96)b | – | 2.15 (1.09–4.23)a | – | – | 1.59 (1.24–2.05)a | 16.12 (2.12–122.46)a | nd | |
| HI1 | nd | na | 5.80 (1.84–18.26)a | na | na | na | na | na | na | na | 4.87 (1.91–12.45)a | na | na | na | |
| HI2 | na | nd | na | 41.84 (2.52–694.23)a | na | na | na | na | na | na | na | na | na | na | |
| I1- | 5.80 (1.84–18.26)a | na | nd | na | na | – | 14.03 (6.35–31.02)a | na | na | na | – | na | na | – | |
| N | na | 41.84 (2.52–694.23)a | na | nd | na | na | na | na | na | 17.84 (5.13–62.07)a | na | na | na | na | |
| FIB | na | na | – | na | na | nd | na | na | na | – | na | na | na | na | |
| Y | na | na | 14.03 (6.35–31.02)a | na | na | na | nd | na | na | na | na | na | na | na | |
| FIC | na | na | na | na | na | na | na | na | nd | na | – | na | na | na | |
| A/C | na | na | na | 17.84 (5.13–62.07)a | na | – | na | na | na | nd | na | na | na | – | |
| FIIAs | 4.87 (1.91–12.45)a | na | – | na | na | na | na | na | – | na | nd | na | na | na | |
| F | na | na | – | na | na | na | na | na | na | – | na | na | na | nd | |
OR > 1, the presence of the replicon type increased with the presence of corresponding replicon types.
OR < 1, the presence of the replicon type decreased with the presence of corresponding replicon types.
Statistically significant association (95% CI did not cross 1) between the presence of plasmids in particular Inc groups and resistant or ESBL-producing strains.
–, no statistically significant association (95% CI cross 1) between the presence of plasmids in particular Inc groups and resistant or ESBL-producing strains.
na, no OR due to the lack of the corresponding replicon types.
nd, no OR because the statistics could not be determined.
Replicon sequence types of Inc F of E. coli (n = 26) and Salmonella (n = 3)
| Species | Strain name | Regions | Provinces | Sources | Year | Resistance genes | Allele number for replicon | FAB formula | ||
|---|---|---|---|---|---|---|---|---|---|---|
| FII, FIIs | FIA | FIB | ||||||||
| CREM 10 | N | CRI | Pork | 2016–2017 | F46 | – | – | F46:A-:B- | ||
| CRES 14 | N | CRI | Pig | 2016–2017 | F46 | – | – | F46:A-:B- | ||
| CRES 7 | N | CRI | Pig | 2016–2017 | F46 | – | B20 | F46:A-:B20 | ||
| FpCa1 | W | RBR | Pig | 2015 | F46 | – | B20 | F46:A-:B20 | ||
| FpEa24 | W | RBR | Pig | 2016–2017 | F46 | – | B20 | F46:A-:B20 | ||
| NK 253 | NE | NKI | Human | 2013–2014 | F46 | – | B20 | F46:A-:B20 | ||
| CRES 20 | N | CRI | Pig | 2016–2017 | F18 | – | B1 | F18:A-:B1 | ||
| MH 95 | NE | MDH | Pork | 2013–2014 | F18 | – | B1 | F18:A-:B1 | ||
| SaEM 37 | E | SKW | Pork | 2016–2017 | F18 | – | B1 | F18:A-:B1 | ||
| E405 | NE | NMA | Pig | 2007–2008 | F2 | – | – | F2:A-:B- | ||
| MH 70 | NE | MDH | Human | 2013–2014 | F2 | – | – | F2:A-:B- | ||
| SaEM 19 | E | SKW | Pork | 2016–2017 | F2 | – | – | F2:A-:B- | ||
| SaEM 29 | E | SKW | Pork | 2016–2017 | F2 | – | – | F2:A-:B- | ||
| SaES 22 | E | SKW | Pig | 2016–2017 | F2 | – | – | F2:A-:B- | ||
| NK 261 | NE | NKI | Human | 2013–2014 | F2 | – | – | F2:A-:B- | ||
| NK 262 | NE | NKI | Human | 2013–2014 | F2 | – | – | F2:A-:B- | ||
| E431 | W | RBR | Pig | 2007–2008 | F2 | – | B40 | F2:A-:B40 | ||
| MH 227 | NE | MDH | Human | 2013–2014 | F29 | – | B10 | F29:A-:B10 | ||
| NK 276 | NE | NKI | Human | 2013–2014 | F46 | – | B24 | F46:A-:B24 | ||
| PLCa 7 | NE | NMA | Pig | 2015 | F2 | – | B20 | F2:A-:B20 | ||
| PLEa 14 | NE | NMA | Pig | 2015 | F100 | – | B13 | F100:A-:B13 | ||
| SaES 46 | E | SKW | Pig | 2016–2017 | F18 | A5, A6 | B1 | F18:A5,6:B1 | ||
| NK 267 | NE | NKI | Human | 2013–2014 | – | A1, A6 | B1 | F-:A1,6:B1 | ||
| CREM 48 | N | CRI | Pork | 2016–2017 | – | – | B24 | F-:A-:B24 | ||
| SaEM 15 | E | SKW | Pork | 2016–2017 | – | – | B24 | F-:A-:B24 | ||
| SaEM 57 | E | SKW | Pork | 2016–2017 | – | – | B24 | F-:A-:B24 | ||
| MH 178.1 | NE | MDH | Pork | 2013–2014 | S1 | – | – | S1:A-:B- | ||
| NSM 11.3 | NE | NKI | Pork | 2016–2017 | S1 | – | – | S1:A-:B- | ||
| CRSS 28.1 | N | CRI | Pig | 2016–2017 | F2 | – | – | F2:A-:B- | ||
N, Northern; NE, North-eastern; W, West; E, East.
CRI, Chiangrai; RBR, Ratchaburi; NKI, Nongkhai; MDH, Mukdaharn; SKW, Sakaew; NMA, Nakornratchsrima.
Both sequences of FII and FIIs were identified to be allele F.
FAB formula was the combination of the sequence type of FII or FIIs:FIA:FIB.
Exactly matched to more than one reference.